The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC).
 
Michael Wotman
No Relationships to Disclose
 
Camilla Oliveira Hoff
Leadership - Rede D'Or São Luiz (I)
Stock and Other Ownership Interests - Oncostar (I)
Honoraria - Bayer (I); Lilly (I)
Consulting or Advisory Role - Bayer (I); Lilly (I)
Research Funding - Exelixis (I); Lilly (I); Novartis (I)
 
Flavia Bonini
No Relationships to Disclose
 
Matthew Sawyer
No Relationships to Disclose
 
Kaiwen Wang
Consulting or Advisory Role - BluPrint Oncology
 
Eduardo Andreazza Dal Lago
No Relationships to Disclose
 
Luana Guimaraes de Sousa
Research Funding - Agenus (Inst); Elevar Therapeutics (Inst)
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year